Patricia Pautier, MD, discusses the results of the phase 2 LMS-02 trial with doxorubicin and trabectedin in uterine and soft tissue leiomyosarcoma.
Patricia Pautier, MD
Advertisement
Articles by Patricia Pautier, MD
Patricia Pautier, MD, discusses limitations in leiomyosarcoma.
Patricia Pautier, MD, discusses remaining challenges in treating patients with metastatic/advanced uterine and soft tissue leiomyosarcoma.
Patricia Pautier, MD, discusses the rationale for the phase 2 LMS-02 trial in uterine and soft tissue leiomyosarcoma.
Patricia Pautier, MD, discusses the toxicity profile of doxorubicin with trabectedin in the phase 2 LMS-02 trial in patients with metastatic/advanced uterine and soft tissue leiomyosarcoma.
Advertisement
Latest Updated Articles
Dr. Pautier on Challenges With Drug Development in LeiomyosarcomaPublished: October 6th 2020 | Updated:
Dr. Pautier on Results of the LMS-02 Trial in Uterine and Soft Tissue SarcomasPublished: October 16th 2020 | Updated:
Dr. Pautier on Remaining Challenges in Advanced Soft Tissue SarcomaPublished: September 11th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5